<DOC>
	<DOCNO>NCT02865044</DOCNO>
	<brief_summary>The objective study evaluate compare acute bioavailability EPA DHA wax ester form provide dietary supplement compare well-studied defined ethyl ester formulation generally healthy men woman .</brief_summary>
	<brief_title>Study Evaluate Acute Bioavailability EPA DHA From DietarySupplement Healthy Men Women</brief_title>
	<detailed_description>A randomize , control two-period crossover study include one screening/baseline visit ( visit 1 , day -7 ) four test visit Period I ( visit 2 , 3 , 4 , 5 ; day 0 , 1 , 2 , 3 ) four test visit Period II ( visit 6 , 7 , 8 , 9 ; day 14 , 15 , 16 , 17 ) least 7-d washout test period . Eighteen healthy adult fast TAG concentration &lt; 200 mg/dL randomly assign one two treatment sequence : receive 8 capsule contain Calanus oil® ( Calanus AS , Tromso , Norway ) supply total 4 g oil provide 260 mg EPA 156 mg/day DHA primarily wax ester , follow 1 capsule supply 1 g oil provide 465 mg EPA 375 mg DHA ethyl ester ( Lovaza® , GlaxoSmithKline , Research Triangle Park , NC ) ; , receive Lovaza follow Calanus Oil . Product dispense in-clinic standardized EPA- DHA- free breakfast meal ( t=0 ) . Blood sample obtain in-clinic t= -30 min , 1 , 2 , 4 , 6 , 8 , 10 12 h timepoints . Subjects provide standardized EPA- DHA-free meal t=4 h t=8 . Subject dismiss clinic t-12 h blood draw return morning day 1 , 2 3 ( day 15 , 16 17 ) 24 h , 48 h 72 h fast blood draw .</detailed_description>
	<criteria>1 . Male female , 1859 year age , inclusive . 2 . BMI ≥18.50 ≤29.99 kg/m2 visit 1 ( day 7 ) . 3 . Fasting TG &lt; 200 mg/dL visit 1 ( day 7 ) . 4 . Score 7 10 Vein Access Scale visit 1 ( day 7 ) . 5 . No health condition would prevent subject fulfilling study requirement judge Investigator basis medical history routine laboratory test result . 6 . Willing refrain consumption fish/seafood ( include shellfish ) , and/or EPA DHAcontaining food supplement 14 prior visit 2 ( day 0 ) throughout study . 7 . Willing limit alcohol consumption 1 drink/d follow visit 1 ( day 7 ) throughout study . 8 . Nonsmoker plan change smoke habit study period . 9 . Willing maintain habitual diet ( exception food restrict ) , physical activity pattern , body weight throughout trial . 10 . Understood study procedure sign form provide informed consent participate study authorize release relevant protect health information study Investigator . 1 . Abnormal laboratory test result clinical significance visit 1 ( day 7 ) , discretion Investigator . One retest allow separate day prior visit 2 ( day 0 ) subject abnormal laboratory test result . 2 . History presence clinically important endocrine ( include type 1 2 diabetes mellitus ) , cardiovascular ( include , limited history myocardial infarction , peripheral arterial disease , stroke ) , pulmonary ( include uncontrolled asthma ) , hepatic , renal , hematologic , immunologic , dermatologic , neurologic , psychiatric biliary disorder . 3 . History presence GI disorder , judgment Investigator , may disrupt normal digestion absorption study product . 4 . History difficulty swallow tablets/capsules could affect ability consume study product . 5 . Extreme dietary habit ( e.g. , Atkins diet , high protein , vegetarian ) , opinion Investigator . 6 . Uncontrolled hypertension ( systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥100 mm Hg ) define blood pressure measure visit 1 ( day 7 ) . One retest allow separate day prior visit 2 ( day 0 ) , subject whose blood pressure exceed either cut point , judgment Investigator . 7 . History presence cancer prior two year , except nonmelanoma skin cancer . 8 . Weight loss gain &gt; 4.5 kg 3 month prior visit 1 ( day 7 ) . 9 . Use medication dietary supplement know alter lipid concentration within 4 week visit 1 ( day 7 ) . Dietary supplement include , limit , follow : sterol/stanol product ; dietary fiber supplement ( include &gt; 1 teaspoon Metamucil® viscous fibercontaining supplement per day ) ; red rice yeast supplement ; garlic supplement ; soy isoflavone supplement ; niacin analogue dosage &gt; 50 mg/day ( others discretion Investigator ) . 10 . Use nonstudy related omega3acid ethyl ester drug ( ) dietary supplement ( ) ≥1.0 g/d EPA , DHA , combination EPA DHA within 4 month visit 1 ( day 7 ) . 11 . Known allergy sensitivity omega3 fatty acid , fish , seafood , ingredient study product study meal . 12 . Active infection use antibiotic within 5 visit 2 6 ( day 0 14 ) . Subjects active infection and/or use antibiotic require wait least 5 infection resolve antibiotic use complete prior first day test period ( visit 2 6 , day 0 14 ) . 13 . Female pregnant , plan pregnant study period , lactating , childbearing potential unwilling commit use medically approve form contraception throughout study period . The method contraception record source documentation . 14 . Exposure nonregistered drug product within 30 prior visit 1 ( day 7 ) . 15 . Recent history ( within 12 month screen ; visit 1 , day 7 ) strong potential alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1½ oz distil spirit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Fatty Acids</keyword>
	<keyword>Fish Oil</keyword>
	<keyword>Marine Copepod</keyword>
	<keyword>Fatty Acid Absorption</keyword>
</DOC>